BioMarin Stock Seen as Buy Opportunity After 12% Drop and Amicus Integration

Key Facts

1BioMarin (BMRN) shares have declined over 12% since January 2025 despite prior optimism.

2The investment thesis centers on the potential of VOXZOGO and two approved therapies from Amicus to drive upside.

Recent analytical reports suggest that BioMarin Pharmaceutical (BMRN) presents an attractive investment opportunity despite its shares declining by over 12% since January 2025. The bullish investment thesis centers on the significant potential of the drug VOXZOGO, alongside two approved therapies acquired through the Amicus transaction. Analysts believe the recent share price weakness does not reflect the true value of the company's expanding rare disease portfolio. Furthermore, the integration of Amicus assets is expected to bolster cash flows and drive long-term growth. Despite broader market volatility, expectations remain optimistic regarding the company's ability to regain price momentum. This assessment reflects a forward-looking view based on the intrinsic value of current and future pharmaceutical assets.